Overview
ACRV market data
Price History
ACRV price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.92 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.21 – $3.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $74.5M · P/B 0.68.
Company News
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) EstimateBenzinga · Aug 12, 2026, 8:23 PM
8-K filing — Acrivon Therapeutics, Inc. (ACRV)SEC EDGAR · Aug 12, 2026, 8:10 PM
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 StudyBenzinga · Aug 5, 2026, 12:32 PM
Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24Benzinga · Jul 21, 2026, 8:32 PM